Scientists sought to understand how the programmed death ligand 1 inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell activation and function in patients with relapsed/refractory multiple myeloma.
[Scientific Reports]
6445218
{6445218:KA66XQD4}
apa
50
1
165646
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-a4e367870a564d40945df5c9fccbdff4%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22KA66XQD4%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Young%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EYoung%2C%20M.%20H.%2C%20Pietz%2C%20G.%2C%20Whalen%2C%20E.%2C%20Copeland%2C%20W.%2C%20Thompson%2C%20E.%2C%20Fox%2C%20B.%20A.%2C%20%26amp%3B%20Newhall%2C%20K.%20J.%20%282021%29.%20Immunomodulation%20by%20durvalumab%20and%20pomalidomide%20in%20patients%20with%20relapsed%5C%2Frefractory%20multiple%20myeloma.%20%3Ci%3EScientific%20Reports%3C%5C%2Fi%3E%2C%20%3Ci%3E11%3C%5C%2Fi%3E%281%29%2C%2016460.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-95902-x%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-95902-x%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DKA66XQD4%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Immunomodulation%20by%20durvalumab%20and%20pomalidomide%20in%20patients%20with%20relapsed%5C%2Frefractory%20multiple%20myeloma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%20H.%22%2C%22lastName%22%3A%22Young%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Greg%22%2C%22lastName%22%3A%22Pietz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Whalen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilbert%22%2C%22lastName%22%3A%22Copeland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ethan%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%20A.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20J.%22%2C%22lastName%22%3A%22Newhall%22%7D%5D%2C%22abstractNote%22%3A%22This%20study%20sought%20to%20understand%20how%20the%20programmed%20death%20ligand%201%20%28PD-L1%29%20inhibitor%20durvalumab%20and%20the%20immunomodulatory%20agent%20pomalidomide%20regulate%20immune%20cell%20activation%20and%20function%20in%20patients%20with%20relapsed%5C%2Frefractory%20%28RR%29%20multiple%20myeloma%20%28MM%29.%20Immunologic%20changes%20in%20peripheral%20blood%20and%20bone%20marrow%20of%20patients%20treated%20with%20durvalumab%20as%20monotherapy%20or%20in%20combination%20with%20pomalidomide%20with%5C%2Fwithout%20dexamethasone%20were%20characterized%20by%20assessing%20subsets%20of%20immune%20cells%20and%20gene%20signatures%20to%20understand%20the%20immunomodulatory%20effect%20of%20the%20treatment.%20Soluble%20PD-L1%20levels%20were%20elevated%20at%20screening%20in%20patients%20with%20RRMM%20but%20did%20not%20correlate%20with%20response%20to%20durvalumab%20combination%20therapy.%20Immune%20cell%20subsets%20were%20increased%20in%20peripheral%20blood%20during%20treatment%20with%20durvalumab%20and%20pomalidomide%2C%20and%20combination%20therapy%20induced%20significant%20gene%20expression%20changes%20in%20the%20MM%20tumor%20microenvironment%20versus%20durvalumab%20alone.%20Estimation%20of%20cell%20populations%20based%20on%20RNA%20sequencing%20data%20revealed%20increased%20monocytes%2C%20neutrophils%2C%20and%20natural%20killer%20cells%20with%20the%20combination%20therapy%2C%20but%20not%20with%20durvalumab%20alone.%20Additionally%2C%20multiplex%20immunofluorescence%20of%20bone%20marrow%20demonstrated%20that%20immune%20populations%20were%20different%20in%20responders%20versus%20nonresponders%20to%20durvalumab%20plus%20pomalidomide%20with%20dexamethasone%20therapy.%20Overall%2C%20durvalumab%20effectively%20blocked%20soluble%20PD-L1%3B%20however%2C%20durvalumab%20monotherapy%20was%20not%20associated%20with%20immunologic%20changes%2C%20which%20were%20observed%20with%20combination%20therapy.%22%2C%22date%22%3A%222021-08-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-021-95902-x%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41598-021-95902-x%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-08-13T00%3A37%3A59Z%22%7D%7D%5D%7D
Young, M. H., Pietz, G., Whalen, E., Copeland, W., Thompson, E., Fox, B. A., & Newhall, K. J. (2021). Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. Scientific Reports, 11(1), 16460. https://doi.org/10.1038/s41598-021-95902-x Cite
